It is concluded that EAM-2201 has the probable to trigger in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and it is evaluated in pooled human liver microsomes. EAM-2201 was incubated with human hepatocytes for three h in the CO2 incubator along with the metabolites https://davidt505bsh8.dailyhitblog.com/profile